一项随机双盲安慰剂对照临床研究:评估合生元医学食品SBD111对绝经后女性骨丢失的临床饮食管理效果
这项为期12个月的研究纳入286名早期绝经后女性,评估合生元医学食品SBD111减少骨丢失的有效性和安全性。SBD111在全队列中未显著减少骨丢失,但在骨量减少和BMI≥30的女性中产生了减少骨丢失的证据。
要点
- SBD111在全队列中未显著减少腰椎骨密度丢失,平均效应量为0.15%(95%CI -0.52%至0.82%)。
- BMI≥30的女性中,SBD111与全髋骨密度丢失减少相关,效应量为0.97%(95%CI 0.015%至1.925%)。
- 骨量减少的女性中,SBD111与股骨颈骨密度丢失轻度减少相关,效应量为0.89%(95%CI -0.277%至2.051%)。
核心结论
- 这些发现表明SBD111未显著减少全队列的骨密度丢失,但试验产生了SBD111减少骨量减少和BMI≥30女性骨丢失的证据。
研究设计与样本
- 前瞻性、多中心、双盲、随机、安慰剂对照临床食品试验(NCT05009875),纳入286名健康、非骨质疏松、绝经后1至6年的女性。
主要发现
- 286名女性[年龄55±3岁(均值±标准差)]入组,221名(77%)完成研究。
- 主要结局:12个月后SBD111与腰椎骨丢失无显著关联[0.15%(-0.52%,0.82%),线性混合效应回归平均效应量(95%CI)]。
- BMI≥30的女性中,SBD111与全髋骨密度丢失减少相关[0.97%(0.015%,1.925%)]。
- 骨量减少的女性中,SBD111与股骨颈骨密度丢失轻度减少相关[0.89%(-0.277%,2.051%)]。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: This 12-month study in 286 early postmenopausal women evaluated the efficacy and safety of SBD111, a synbiotic medical food, in reducing bone loss. SBD111 did not significantly reduce bone loss for the full cohort, but did produce evidence of reduced bone loss in women with osteopenia and BMI ≥ 30. PURPOSE: To determine the efficacy of SBD111, a synbiotic medical food comprising probiotics and prebiotics, in reducing bone loss in women post-menopause, including prespecified subpopulations of women with osteopenia or elevated BMI. METHODS: In this prospective, multicenter, double-blind, randomized, placebo-controlled clinical food trial (NCT05009875), 286 healthy, non-osteoporotic women between 1 and 6 years post-menopause were enrolled and consumed SBD111 (4.75 × 1010 colony forming units) or placebo (maltodextrin) capsules twice daily for 12 months. The primary endpoint was change in areal BMD at the lumbar spine (LS). Secondary endpoints included change in areal BMD at the femoral neck (FN) and total hip (TH), trabecular volumetric BMD at the LS, markers of bone turnover and inflammation, and safety. Changes in gut microbiome composition were exploratory. The hypotheses being tested were formulated before data collection. RESULTS: Two hundred eighty-six women [age 55 ± 3 years (mean ± standard deviation)] were enrolled, with 221 (77%) completing the study. For the primary outcome, SBD111 administration was not associated with significantly less bone loss in the LS after 12 months [0.15% (- 0.52%, 0.82%), mean effect size (95% CI) by linear mixed-effects regression]. However, SBD111 was associated with reduced BMD loss in the TH for women with BMI ≥ 30 [0.97% (0.015%, 1.925%)] and modestly reduced BMD loss in the FN for women with osteopenia [0.89% (- 0.277%, 2.051%)]. CONCLUSIONS: These findings indicate SBD111 did not significantly reduce BMD loss for the full cohort. However, the trial produced evidence that SBD111 reduced bone loss in women with osteopenia and BMI ≥ 30.
引用
- Schott EM, Charbonneau MR, Kiel DP, et al. A randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy of the synbiotic medical food, SBD111, for the clinical dietary management of bone loss in menopausal women. Osteoporos Int. 2025. PMID: 40815418. doi:10.1007/s00198-025-07650-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。